Harrington Discovery Institute at University Hospitals
VC Fund
Harrington Discovery Institute at University Hospitals is a VC fund focused on Biotechnology and Health Care. Harrington Discovery Institute at University Hospitals aims to advance medicine and society.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Harrington Discovery Institute at University Hospitals invests in
Stages Harrington Discovery Institute at University Hospitals invests in
Countries Harrington Discovery Institute at University Hospitals invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Rahul Aras
|
|||
Scott Woodward
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 4 (67%)
- Health Care 3 (50%)
- Therapeutics 3 (50%)
- Medical 2 (33%)
- Life Science 2 (33%)
Stage
- Seed 2 (33%)
- Series A 2 (33%)
- Funding Round 1 (17%)
Country
- United States 2 (33%)
- United Kingdom 2 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Rahul Aras
Business Development Consultant
|
Business Development Consultant | Total investments: 0 | Find email | |
|
Scott Woodward
Business Development Advisor, Harrington Discovery Institute Therapeutics Development Team
|
Business Development Advisor, Harrington Discovery Institute Therapeutics Development Team | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Epitopea
|
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $31M / Seed / Oct 24, 2024 | |
AlveoGene
|
AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy. | Seed / Sep 14, 2023 | |
PIC Therapeutics
|
PIC Therapeutics is a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation. The company is modulating oncogene translation to dramatically improve cancer patient outcomes. Their precision-based therapeutics target the “master switch” of cancer signaling pathways, selectivelyblocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Its selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.PIC Therapeutics was founded in 2016 and is headquartered in Natick, Massachusetts, United States. | $35M / Series A / Oct 19, 2022 | |
|
Epitopea
|
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $13.1M / Seed / Apr 25, 2022 | |
Allyx Therapeutics
|
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preservecognition in patients. | $7.6M / Jun 01, 2021 | |
|
Allyx Therapeutics
|
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preservecognition in patients. | $7.6M / Series A / Jun 01, 2021 |
Co-Investors
Advent Life Sciences
4 deals together
Bristol-Myers Squibb
2 deals together
Cambridge Innovation Capital
2 deals together
CTI Life Sciences Fund
2 deals together
Elm Street Ventures
2 deals together
Fonds de solidarité FTQ
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Harrington Discovery Institute at University Hospitals invest in?
Harrington Discovery Institute at University Hospitals invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Harrington Discovery Institute at University Hospitals?
Public channels for Harrington Discovery Institute at University Hospitals include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Harrington Discovery Institute at University Hospitals?
The team at Harrington Discovery Institute at University Hospitals includes Rahul Aras (Business Development Consultant) and Scott Woodward (Business Development Advisor, Harrington Discovery Institute Therapeutics Development Team). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
